What Is Travaris 440 mg/20 ml Indications and Uses?

Adjuvant Breast Cancer : Travaris 440 mg/20 ml (Trastuzumab) is indicated for adjuvant treatment of HER2 overexpressing node-positive or node-negative ER/PR negative or with one high-risk feature breast cancer. as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel ... Read more Adjuvant Breast Cancer : Travaris 440 mg/20 ml (Trastuzumab) is indicated for adjuvant treatment of HER2 overexpressing node-positive or node-negative ER/PR negative or with one high-risk feature breast cancer. as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline-based therapy. Metastatic Breast Cancer : Travaris is indicated: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in a patient who has received one or more chemotherapy regimens for metastatic disease. overexpressing breast cancer in patient. Metastatic Gastric Cancer : Travaris is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.

Pharmacology (Source, Chemical and Physical Composition) Of Travaris 440 mg/20 ml

The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Travaris 440 mg/20 ml (Trastuzumab) has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Trastuzumab is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro, Trastuzumab-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.

Drug Interactions of Travaris 440 mg/20 ml

Patients who receive anthracycline after stopping Travaris 440 mg/20 ml (Trastuzumab) may be at increased risk of cardiac dysfunction because of Travaris’s long washout period based on population PK analysis. If possible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping Travaris. If anthracyclines are used, the patient’s cardiac function should be monitored carefully.

Side Effects of Travaris 440 mg/20 ml

The most serious adverse reactions caused by Travaris 440 mg/20 ml (Trastuzumab) includes Cardiomyopathy, Infusion Reactions, Embryo-Fetal Toxicity, Pulmonary Toxicity, Exacerbation of Chemotherapy-Induced Neutropenia. The most common adverse reactions in patients receiving Travaris in the adjuvant and metastatic breast cancer setting are fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.

Precautions And Warnings for Travaris 440 mg/20 ml

Cardiomyopathy : Travaris 440 mg/20 ml (Trastuzumab) can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death. Travaris can also cause asymptomatic decline in left ventricular ejection fraction (LVEF). There is a 4-6 fold increase in the incidence of symptomatic myocardial dysfunction among patients receiving Travaris as a single agent or in combination therapy compared with those not receiving Travaris. The highest absolute incidence occurs when Travaris is administered with an anthracycline. Withhold Travaris for ≥ 16% absolute decrease in LVEF from pre treatment values or an LVEF value below institutional limits of normal and ≥ 10% absolute decrease in LVEF from pretreatment values. The safety of continuation or resumption of Travaris in patients with Travaris-induced left ventricular cardiac dysfunction has not been studied. Cardiac Monitoring : Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan. The following schedule is recommended: Baseline LVEF measurement immediately prior to initiation of Travaris LVEF measurements every 3 months during and upon completion of Travaris Repeat LVEF measurement at 4 week intervals if Travaris is withheld for significant left ventricular cardiac dysfunction. LVEF measurements every 6 months for at least 2 years following completion of Travaris as a component of adjuvant therapy. Infusion Reactions : Infusion reactions consist of a symptom complex characterized by fever and chills, and on occasion included nausea, vomiting, pain (in some cases at tumor sites), headache, dizziness, dyspnea, hypotension, rash, and asthenia. Serious and fatal infusion reactions have been reported. Severe reactions, which include bronchospasm, anaphylaxis, angioedema, hypoxia, and severe hypotension, were usually reported during or immediately following the initial infusion. However, the onset and clinical course were variable, including progressive worsening, initial improvement followed by clinical deterioration, or delayed post-infusion events with rapid clinical deterioration. For fatal events, death occurred within hours to days following a serious infusion reaction. Interrupt Travaris infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). Patients should be evaluated and carefully monitored until complete resolution of signs and symptoms. Permanent discontinuation should be strongly considered in all patients with severe infusion reactions. There are no data regarding the most appropriate method of identification of patients who may safely be retreated with Travaris after experiencing a severe infusion reaction. Prior to resumption of Travaris infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. While some patients tolerated Travaris infusions, others had recurrent severe infusion reactions despite pre-medications. Embryo-Fetal Toxicity : Travaris can cause fetal harm when administered to a pregnant woman. Use of Travaris during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of Travaris. Pulmonary Toxicity : Travaris use can result in serious and fatal pulmonary toxicity. Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis. Such events can occur as sequelae of infusion reactions. Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest, appear to have more severe toxicity. Exacerbation of Chemotherapy-Induced Neutropenia : In randomized, controlled clinical trials, the per-patient incidences of NCI-CTC Grade 3-4 neutropenia and of febrile neutropenia were higher in patients receiving Travaris in combination with myelosuppressive chemotherapy as compared to those who received chemotherapy alone. The incidence of septic death was similar among patients who received Travaris and those who did not.

Use During Pregnancy and Lactation

It can cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to the initiation of Travaris 440 mg/20 ml (Trastuzumab). Advise pregnant women and females of reproductive potential that exposure to Trastuzumab during pregnancy or within 7 months prior to conception can result in fetal harm. Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of Trastuzumab. There is no information regarding the presence of Trastuzumab in human milk, the effects on the breastfed infant, or the effects on milk production.

Therapeutic Class

Targeted Cancer Therapy

Storage Conditions of It

Store the vial in original carton at 2°-8°C. Protect from light. Keep out of the reach of children. Store reconstituted Travaris in the refrigerator at 2°C to 8°C, discard unused Travaris after 28 days. If Travaris is reconstituted with SWFI without preservative, use immediately and discard any unused portion. Do not freeze. The solution of Travaris for infusion diluted in 0.9% Sodium Chloride Injection, USP, should be stored at 2°C to 8°C for no more than 24 hours prior to use. Do not freeze. Thanks for using MedEx! How would you rate your experience so far?